Anti-Müllerian Hormone Dynamics in Female Reproductive Health

Anti-Müllerian hormone (AMH) is a glycoprotein produced by granulosa cells of small growing ovarian follicles and serves as a quantitative marker of functional ovarian reserve. Circulating AMH exhibits characteristic age-related changes: it rises through childhood, plateaus in early adulthood, and then declines progressively towards menopause. This dynamic profile provides insight into the remaining pool of antral and preantral follicles and underpins clinical applications in fertility assessment, prediction of response to ovarian stimulation and individualisation of assisted reproduction protocols. Beyond its role as a static biomarker, emerging evidence implicates AMH in central neuroendocrine regulation, metabolic comorbidities and the pathogenesis of disorders such as polycystic ovary syndrome. Environmental, genetic and lifestyle factors—including body mass index, nutritional status and ethnic variation—modulate AMH levels, adding complexity to interpretation. Advances in automated assays have improved measurement consistency, yet the absence of a global standard limits assay comparability. Overall, understanding AMH dynamics is essential for personalised reproductive counselling, optimisation of fertility treatments and timely interventions to preserve ovarian function.

Research from Nature Portfolio

Research has uncovered a novel endocrine role for AMH in regulating follicle-stimulating hormone (FSH) secretion prior to puberty. Experimental studies in immature rodents demonstrate that AMH receptor activation in pituitary gonadotropes enhances FSH synthesis through Smad-dependent signalling, distinct from luteinising hormone regulation. This finding reveals a feedback loop whereby ovarian AMH output influences central gonadotrope activity, contributing to sexual dimorphism in early reproductive development. Such insights expand the conceptual framework of AMH from a purely ovarian reserve marker to an active participant in hypothalamic–pituitary–ovarian axis regulation.

Anti-Müllerian Hormone Dynamics in Female Reproductive Health publication trend

The graph below shows the total number of articles in anti-müllerian hormone dynamics in female reproductive health across all publications each year (not limited to Nature Index journals).

Technical terms

Anti-Müllerian hormone (AMH): A peptide hormone secreted by granulosa cells of preantral and small antral ovarian follicles that reflects the size of the growing follicle pool and is used as a marker of functional ovarian reserve.

Ovarian reserve: The quantity and quality of primordial and growing follicles remaining in the ovaries, determining a woman’s reproductive potential and lifespan.

Antral follicle count (AFC): The number of small fluid-filled follicles (2–10 mm) visualised by ultrasound at the beginning of a menstrual cycle, indicative of ovarian reserve.

Follicle-stimulating hormone (FSH): A pituitary gonadotropin that stimulates follicular growth in the ovary; its dose and serum levels are used to tailor ovarian stimulation protocols.

References

1. A Validated Model of Serum Anti-Müllerian Hormone from Conception to Menopause. PLOS ONE (2011).
2. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. The Journal of Clinical Endocrinology & Metabolism (2020).
3. Anti‐Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers. Disease Markers (2016).
4. Anti-Müllerian hormone: a new actor of sexual dimorphism in pituitary gonadotrope activity before puberty. Scientific Reports (2016).
5. Anti-Müllerian Hormone Concentrations in Women of Different Reproductive Age and the Chances of IVF Outcome: A Paradigm Shift is needed.. Aging and Disease (2024).
6. Assessment of Nutritional Status and Its Influence on Ovarian Reserve: A Systematic Review. Nutrients (2023).
7. Potential Mechanisms for Racial and Ethnic Differences in Antimüllerian Hormone and Ovarian Reserve. International Journal of Endocrinology (2013).